Treatment strategy after PSMA for advanced Prostate Cancer
Szu-ju Chen, Kun-yuan Chiu
Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
Purpose: Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein on the surface of prostate cells and is highly expressed in poorly dfferentiated, metastatic, and castration-resistant prostate cancer. PSMA has gained increasing interesting as target molecule on image diagnosis and treatment for advanced prostate cancer due to labelled antibody can bind its extracellular domain. Therefore, it can be early localization of metastatic cancer cells than conventional image technique.
Materials and Methods: We enrolled 9 patients with prostate cancer which pathological staging above T2. All patients underwent radical prostatectomy (age ranged from 60 to 78, mean 69-year-old) and presented cancer progression after hormone therapy.
Results: They were further diagnosed by 68Ga-PSMA–PET imaging in combination with multiparametric MRI (mpMRI) for cancer localization after castration (mCRPC). All patients under PSMA-based radioligand therapy. The result will be presented.
Conclusions: In conclusion, the application of PSMA is becoming mature for the diagnosis and treatment of mCRPC based on our preliminary result.